The impact of nanomedicine development on North-South equity and equal opportunities in healthcare

Studies in Ethics, Law, and Technology

Volumn 3, Issue 3, 2009, Pages

  Tyshenko, Michael G ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Drug development; Equity; Nanomedicine; North countries; South countries

Indexed keywords

EID: 75149190918     PISSN: None     EISSN: 19416008     Source Type: Journal    
DOI: 10.2202/1941-6008.1118     Document Type: Article

References (49)

1. Andrianov A.K. and Payne L.G. 1998. Polymeric carriers for oral uptake of microparticulates. Adv Drug Deliv Rev. 34(2-3): 155-170.
2. Andrianov A.K., Jenkins S.A., Payne L.G. and Roberts B.E. 1996. Hydrogel microencapsulated vaccines, US Patent Number 5,529,777. Available: http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p= 1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=9&f=G&l=50&co1= AND&d=PTXT&s1=Andrianov&s2=nano&OS=Andrianov+AND+nano&RS= Andrianov+AND+nano.
3. Bill and Melinda Gates Foundation. 2007. Bill and Melinda Gates Call for New Global Commitment to Chart a Course for Malaria Eradication. October 17. Available: http://www.gatesfoundation.org/press-releases/Pages/course-for- malaria-eradication-071017-2.aspx.
4. Bill and Melinda Gates Foundation. 2009. Chinese Government and Foundation Announce Partnership to Fight Tuberculosis. April 1. Available: http://www.gatesfoundation.org/press-releases/Pages/partnering-with-chinese- government-to-stop-tb-090331.aspx.
5. Black R.E. 1993. Epidemiology of diarrhoeal disease: implications for control by vaccines. Vaccine. 11(2):100-106
6. Bugusu B. 2008. Improving food through nanoscience. Food Technology.September: 34-39. Available: http://members.ift.org/NR/rdonlyres/ D8FF91A0-201B-4E45-85F0-34DAA5FECB4D/0/0908feat-nano.pdf.
7. Burnett K. and Tyshenko M.G. 2010. A comparison of human capital levels and the future prospect of the nanotechnology industry in early sector investors and recent emerging markets. International Journal of Nanotechnology. 7(2-3):187-208.
8. Centers for Disease Control and Prevention. 2003. Update: global measles control and mortality reduction-worldwide, 1991-2001. MMWR Morb Mortal Wkly Rep. May 23. 52(20): 471-475
9. Chen H., Roco M.C., Li X. and Lin Y. 2008. Trends in nanotechnology patents. Nature Nanotechnology 3, 123-125.
10. Compañó R. and Hullman A. 2002. Forecasting the development of nanotechnology with the help of science and technology indicators, Nanotechnology, 13: 243-247
11. Court E, Daar AS, Martin E, Acharya T, Singer PA (2004) Will Prince Charles et al diminish the opportunities of developing countries in nanotechnology? Available: http://nanotechweb.org/cws/article/indepth/18909.
12. Darshan S. and Tyshenko M.G. 2010. Identifying recent trends in nanomedicine development. International Journal of Nanotechnology. 7(2-3): 173-186
13. Donovan B.W., Reuter J.D., Cao Z., Myc A., Johnson K.J. and Baker JR Jr. 2000. Prevention of murine influenza A virus pneumonitis by surfactant nanoemulsions. Antivir Chem Chemother. 11(1):41-49
14. Girard M.P., Steele D., Chaignat C.L. and Kieny M.P. 2006. A review of vaccine research and development: human enteric infections. Vaccine. 24(15): 2732-2750
15. Hassan MH. 2005. Nanotechnology. Small things and big changes in the developing world. Science. 309(5731): 65-66
16. Henry Kaiser Family Foundation. 2009. Clinton Foundation, Global Fund, World Bank, UNICEF Extend Low-Cost Generic AIDS Drug Prices to More Than 100 Countries, April 06, 2004. Available: http://www.kaisernetwork.org/daily- reports/rep-index.cfm?hint=1&DR-ID=23059.
17. Hullmann A. 2006. The economic development of nanotechnology - an indicators based analysis, European Commission, DG Research, Unit "Nano S&T -Convergent Science and Technologies". Available: http://cordis.europa.eu/nanotechnology.
18. Kosek M, Bern C, Guerrant RL. 2003. The global burden of diarrhoeal disease, as estimated from studies published between 1992 and 2000. Bull World Health Organ. 81(3): 197-204.
19. Kreuter J. 1994. Drug targeting with nanoparticles. Eur J Drug Metab Pharmacokinet. 19(3): 253-256
20. Kreuter J. 1996. Nanoparticles and microparticles for drug and vaccine delivery. J Anat. 189(3): 503-505 (Pubitemid 27011002)
21. Landers J.J., Cao Z., Lee I., Piehler L.T., Myc P.P., Myc A., Hamouda T., Galecki A.T., Baker J.R. Jr. 2002. Prevention of influenza pneumonitis by sialic Acidconjugated dendritic polymers. J Infect Dis. 186(9): 1222-1230
22. Lopez A.D., Mathers C.D., Ezzati M., Jamison D.T. and Murray C.J. 2006. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet. 367(9524): 1747-1757
23. Lori F., Trocio J., Bakare N., Kelly L.M. and Lisziewicz, J. 2005. DermaVir, a novel HIV immunisation technology. Vaccine. 23(17-18): 2030-2034
24. Lori F., Calarota S.A. and Lisziewicz J. 2007. Nanochemistry-based immunotherapy for HIV-1. Curr Med Chem. 14(18): 1911-1919
25. Lown B. and Banerjee A. 2006. The developing world in The New England Journal of Medicine. Globalization and Health. 2(3): 1-5.
26. Maclurcan D.C. 2005. Nanotechnology and developing countries part 2: what realities? International Journal of Nanotechnology Online. October. 1: 1-19. Available: http://www.azonano.com/Details.asp?ArticleID=1429
27. Moghimi S.M., Hunter A.C. and Murray J.C. 2005. Nanomedicine: current status and future prospects, FASEB Journal. 19(3): 311-330.
28. Mnyusiwalla A., Daar A.S. and Singer P.A. 2003. Mind the gap: science and ethics in nanotechnology. Nanotechnology. 14: R9-13.
29. Murray C.J.L., Lopez A.D., Mathers C.D. and Stein C. 2001. The global burden of disease 2000 project: aims, methods and data sources. Research Paper No.01 .1. Burden of Disease Unit, Harvard University, Cambridge. USA. Available: http://www.hsph.harvard.edu/burdenofdisease/publications/papers/gbd2000.pdf.
30. Myc A., Kukowska-Latallo J.F., Bielinska A.U., Cao P., Myc P.P., Janczak K., Sturm T.R., Grabinski M.S., Landers J.J., Young K.S., Chang J., Hamouda T., Olszewski M.A., Baker J.R. Jr. 2003. Development of immune response that protects mice from viral pneumonitis after a single intranasal immunization with influenza A virus and nanoemulsion. Vaccine. 21(25-26): 3801-3814
31. Niyogi SK. 2005. Shigellosis. J. Microbiol. 43(2):133-43.
32. OECD. 2008. DAC list of ODA recipients, effective for reporting on 2008, 2009 and 2010 flows. Paris, France. Available: http://www.oecd.org/dataoecd/62/ 48/41655745.pdf.
33. Patil R. 2005. If tomorrow comes. Available: http://www.indianexpress. com/full-story.php?content-id=62323.
34. Peek L.J., Middaugh C.R. and Berkland C. 2008. Nanotechnology in vaccine delivery. Adv Drug Deliv Rev. 60(8): 915-928
35. Plus News. 2009. Clinton Foundation closes deal to slash cost of second-line ARVs. September 30. Available: http://www.plusnews.org/Report.aspx? ReportId=85623.
36. Roco M.C. 2005. International perspective on government nanotechnology funding in 2005. Journal of Nanoparticle Research. 7: 707-712.
37. Salamanca-Buentello F, Persad DL, Court EB, Martin DK, Daar AS, Singer PA. 2005. Nanotechnology and the developing world. PLoS Med. 2(5):e97.
38. Singer P.A. and Daar A.S. 2001. Harnessing genomics and biotechnology to improve global health equity. Science 294: 87-89
39. Singh K.K. and Vingkar S.K. 2008. Formulation, antimalarial activity and biodistribution of oral lipid nanoemulsion of primaquine. Int J Pharm. 347(1-2): 136-143
40. Staton D.M. and Harding M.H. 2004. Protecting child health worldwide. Implementation is the biggest challenge slowing efforts to reduce childhood morbidity and mortality in developing countries. Pediatr Ann. 33(10): 647-655
41. Theron J., Walker J.A. and Cloete T.E. 2008. Nanotechnology and water treatment: applications and emerging opportunities. Crit Rev Microbiol. 34(1): 43-69.
42. Tyshenko M.G. 2010. Nanotechnology innovation as a deus ex machina and potential effects on sustainability in a global context. International Journal of Nanotechnology. 7(2-3): 209-223.
43. UC Atlas. 2009. UC atlas of global inequity. Cause of death. Available: http://ucatlas.ucsc.edu/cause.php.
44. UNAIDS. 2008. 07 UNAIDS annual report. Geneva, Switzerland. pp. 51. Available:http://data.unaids.org/pub/Report/2008/jc1535-annual-report07-en.pdf
45. Wagner V., Dullaart A., Bock A.K. and Zweck A. 2006. The emerging nanomedicine landscape. Nat Biotechnol. 24(10): 1211-1217
46. WHO. 1999. Chapter 2. Six diseases cause 90% of infectious disease deaths in Removing Obstacles to Healthy Development. Geneva, Switzerland. Pp. 68. Available: *http://www2.alliance-hpsr.org/infectious-disease-report/pages/ ch2text.html.
47. WHO. 2009. Initiative for vaccine research (IVR). Available: http://www.who.int/vaccine-research/diseases/diarrhoeal/en/index4.html
48. Xue D. and Tisdell C. 1999. Safety and socio-economic issues raised by modern biotechnology. Working paper No. 36. Economics, Ecology and Environment Working Papers from University of Queensland, School of Economics, Queensland, Australia. Available: http://ageconsearch.umn.edu/bitstream/47995/2/WP36.pdf
49. Zhou P. 2001. North-South dialogue. Tiempo - Issue 40/41, September 2001. Available online: http://www.tiempocyberclimate.org/portal/archive/issue4041/ t4041a1.htm.